Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. The failure rate of treatment for its subsets is still very high. CXC chemokine, secreted by a variety of cells, is a vital component in the immune process. It also participated in the growth, development, and metastasis of tumors. This study aimed to explore the prognosis of CXC chemokines in DLBCL and the relationship with immune infiltration through bioinformatics analysis. Methods: We systematically analyzed the expression level and prognostic value of CXC chemokines in DLBCL patients, and the correlation between CXC chemokines and tumor immune infiltration through databases, such as Oncomine, GEO, GEPIA, GeneMANIA, DAVID, HPA, GenomicScape, and TIMER2.0. Results: With the comprehensive analysis of different databases, we found that CXC chemokines (CXCL1/2/5/6/7/8/9/10/11/12/13/14) had significantly higher transcription levels in DLBCL patients vs. the control groups. The up-regulation mRNA levels of CXCL1/2/6/7/10/12 were associated with poor prognoses in DLBC patients. Further enrichment analysis of CXC chemokines and their receptors revealed that they were related to the infiltration and metastasis of immune cells. Besides, we found that the expression of CXCL9/10/11 were significantly correlated with tumor-infiltrating lymphocytes (TILs) (B cells, CD8+ T cells, CD4+ T cells, macrophages, Treg cells, and NK cells) and immune checkpoints in DLBCL. Conclusion: Our study may provide novel understandings for CXC chemokines as immunotherapeutic targets and prognostic biomarkers in diffuse large B-cell lymphoma through systematic analysis.
| Published in | Cancer Research Journal (Volume 10, Issue 1) |
| DOI | 10.11648/j.crj.20221001.11 |
| Page(s) | 1-15 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Diffuse Large B-cell Lymphoma (DLBCL), Immune Infiltration, Prognosis, Biomarker, Bioinformatics Analysis
| [1] | Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018, 50 (1): 74-87. |
| [2] | N. NV. In vivo modeling of diffuse large B cell lymphoma (DLBCL) with the myeloid differentiation primary response gene 88 (MYD88) L265P mutation. Translational Cancer Research 2016, 5 (S4). |
| [3] | Thieblemont C, Bernard S, Meignan M, Molina T. Optimizing initial therapy in DLBCL. Best Pract Res Clin Haematol 2018, 31 (3): 199-208. |
| [4] | Kersten MJ, Spanjaart AM, Thieblemont C. CD19-directed CAR T-cell therapy in B-cell NHL. Curr Opin Oncol 2020, 32 (5): 408-17. |
| [5] | Xie W, Medeiros LJ, Li S, Yin CC, Khoury JD, Xu J. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep 2020, 15 (4): 372-81. |
| [6] | Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol Res 2019, 7 (3): 355-62. |
| [7] | Cabrero-de Las Heras S, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol 2018, 24 (42): 4738-49. |
| [8] | Zeng Q, Sun S, Li Y, Li X, Li Z, Liang H. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment. Front Oncol 2019, 9: 1555. |
| [9] | Du H, Gao L, Luan J, Zhang H, Xiao T. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges. Acta Haematol 2019, 142 (2): 64-70. |
| [10] | Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother 2013, 62 (9): 1475-84. |
| [11] | Liang K, Liu Y, Eer D, Liu J, Yang F, Hu K. High CXC Chemokine Ligand 16 (CXCL16) Expression Promotes Proliferation and Metastasis of Lung Cancer via Regulating the NF-κB Pathway. Med Sci Monit 2018, 24: 405-11. |
| [12] | Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res 2013, 41: D991-D5. |
| [13] | Dybkær K, Bøgsted M, Falgreen S, Bødker JS, Kjeldsen MK, Schmitz A, Bilgrau AE, Xu-Monette ZY, Li L, Bergkvist KS, Laursen MB, Rodrigo-Domingo M, Marques SC, Rasmussen SB, Nyegaard M, Gaihede M, Møller MB, Samworth RJ, Shah RD, Johansen P, El-Galaly TC, Young KH, Johnsen HE. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol 2015, 33 (12): 1379-88. |
| [14] | Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6 (1): 1-6. |
| [15] | Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017, 45 (W1): W98-W102. |
| [16] | Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris Q. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010, 38: W214-W20. |
| [17] | Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4 (1): 44-57. |
| [18] | Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA-K, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist P-H, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F. Proteomics. Tissue-based map of the human proteome. Science 2015, 347 (6220): 1260419. |
| [19] | Kassambara A, Rème T, Jourdan M, Fest T, Hose D, Tarte K, Klein B. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. PLoS Comput Biol 2015, 11 (1): e1004077. |
| [20] | Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020, 48 (W1): W509-W14. |
| [21] | Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346 (25): 1937-47. |
| [22] | Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459 (7247): 717-21. |
| [23] | Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403 (6769): 503-11. |
| [24] | Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194 (11): 1639-47. |
| [25] | Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJM, Klapper W, Falini B, von Heydebreck A, Metzler D, Bräuninger A, Hansmann M-L, Küppers R. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008, 205 (10): 2251-68. |
| [26] | Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005, 37 (4): 382-90. |
| [27] | Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, Kohler S. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol 2003, 120 (5): 865-70. |
| [28] | Amedei A, Prisco D, D' Elios MM. The use of cytokines and chemokines in the cancer immunotherapy. Recent Pat Anticancer Drug Discov 2013, 8 (2): 126-42. |
| [29] | Bikfalvi A, Billottet C. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment. Am J Physiol Cell Physiol 2020, 318 (3): C542-C54. |
| [30] | Susek KH, Karvouni M, Alici E, Lundqvist A. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment. Front Immunol 2018, 9: 2159. |
| [31] | Hong JY, Ryu KJ, Lee JY, Park C, Ko YH, Kim WS, Kim SJ. Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol 2017, 35 (4): 480-6. |
| [32] | Manfroi B, McKee T, Mayol JF, Tabruyn S, Moret S, Villiers C, Righini C, Dyer M, Callanan M, Schneider P, Tzankov A, Matthes T, Sturm N, Huard B. CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. Cancer Res 2017, 77 (5): 1097-107. |
| [33] | Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012, 87 (9): 865-9. |
| [34] | Koper OM, Kamińska J, Sawicki K, Kemona H. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med 2018, 27 (6): 849-56. |
| [35] | Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz H-J. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 2018, 63: 40-7. |
| [36] | Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197 (11): 1537-49. |
| [37] | Lim SY, Yuzhalin AE, Gordon-Weeks AN, Muschel RJ. Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 2016, 7 (19): 28697-710. |
| [38] | Roy I, Getschman AE, Volkman BF, Dwinell MB. Exploiting agonist biased signaling of chemokines to target cancer. Mol Carcinog 2017, 56 (3): 804-13. |
| [39] | Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget 2013, 4 (12): 2171-85. |
| [40] | Sermer D, Brentjens R. CAR T-cell therapy: Full speed ahead. Hematol Oncol 2019, 37 Suppl 1: 95-100. |
| [41] | Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res 2019, 7 (4): 644-57. |
| [42] | Zhang L, Du H, Xiao T-w, Liu J-z, Liu G-z, Wang J-x, Li G-y, Wang L-x. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma. Biomed Pharmacother 2015, 75: 83-7. |
| [43] | Zhang T, Ren T, Song Z, Zhao J, Jiao L, Zhang Z, He J, Liu X, Qiu L, Li L, Zhou S, Meng B, Zhai Q, Ren X, Qian Z, Wang X, Zhang H. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3 CD8 T Cells and Survival in Diffuse Large B Cell Lymphoma. J Immunol Res 2020: 6968595. |
| [44] | Liu Y, Guo X, Zhan L, Wang L, Wang X, Jiang M. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients. Comput Math Methods Med 2021: 4468140. |
| [45] | Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol 2020, 200 (2): 108-19. |
| [46] | Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer 2020, 8 (2): e000957. |
APA Style
Yuli Cao, Fenling Zhou, Cuilan Deng, Gexiu Liu. (2022). Comprehensive Analysis of the Prognosis and Correlations with Immune Infiltration of CXC Chemokine Family Members in Diffuse Large B-cell Lymphoma. Cancer Research Journal, 10(1), 1-15. https://doi.org/10.11648/j.crj.20221001.11
ACS Style
Yuli Cao; Fenling Zhou; Cuilan Deng; Gexiu Liu. Comprehensive Analysis of the Prognosis and Correlations with Immune Infiltration of CXC Chemokine Family Members in Diffuse Large B-cell Lymphoma. Cancer Res. J. 2022, 10(1), 1-15. doi: 10.11648/j.crj.20221001.11
AMA Style
Yuli Cao, Fenling Zhou, Cuilan Deng, Gexiu Liu. Comprehensive Analysis of the Prognosis and Correlations with Immune Infiltration of CXC Chemokine Family Members in Diffuse Large B-cell Lymphoma. Cancer Res J. 2022;10(1):1-15. doi: 10.11648/j.crj.20221001.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20221001.11,
author = {Yuli Cao and Fenling Zhou and Cuilan Deng and Gexiu Liu},
title = {Comprehensive Analysis of the Prognosis and Correlations with Immune Infiltration of CXC Chemokine Family Members in Diffuse Large B-cell Lymphoma},
journal = {Cancer Research Journal},
volume = {10},
number = {1},
pages = {1-15},
doi = {10.11648/j.crj.20221001.11},
url = {https://doi.org/10.11648/j.crj.20221001.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20221001.11},
abstract = {Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. The failure rate of treatment for its subsets is still very high. CXC chemokine, secreted by a variety of cells, is a vital component in the immune process. It also participated in the growth, development, and metastasis of tumors. This study aimed to explore the prognosis of CXC chemokines in DLBCL and the relationship with immune infiltration through bioinformatics analysis. Methods: We systematically analyzed the expression level and prognostic value of CXC chemokines in DLBCL patients, and the correlation between CXC chemokines and tumor immune infiltration through databases, such as Oncomine, GEO, GEPIA, GeneMANIA, DAVID, HPA, GenomicScape, and TIMER2.0. Results: With the comprehensive analysis of different databases, we found that CXC chemokines (CXCL1/2/5/6/7/8/9/10/11/12/13/14) had significantly higher transcription levels in DLBCL patients vs. the control groups. The up-regulation mRNA levels of CXCL1/2/6/7/10/12 were associated with poor prognoses in DLBC patients. Further enrichment analysis of CXC chemokines and their receptors revealed that they were related to the infiltration and metastasis of immune cells. Besides, we found that the expression of CXCL9/10/11 were significantly correlated with tumor-infiltrating lymphocytes (TILs) (B cells, CD8+ T cells, CD4+ T cells, macrophages, Treg cells, and NK cells) and immune checkpoints in DLBCL. Conclusion: Our study may provide novel understandings for CXC chemokines as immunotherapeutic targets and prognostic biomarkers in diffuse large B-cell lymphoma through systematic analysis.},
year = {2022}
}
TY - JOUR T1 - Comprehensive Analysis of the Prognosis and Correlations with Immune Infiltration of CXC Chemokine Family Members in Diffuse Large B-cell Lymphoma AU - Yuli Cao AU - Fenling Zhou AU - Cuilan Deng AU - Gexiu Liu Y1 - 2022/01/21 PY - 2022 N1 - https://doi.org/10.11648/j.crj.20221001.11 DO - 10.11648/j.crj.20221001.11 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 1 EP - 15 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20221001.11 AB - Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. The failure rate of treatment for its subsets is still very high. CXC chemokine, secreted by a variety of cells, is a vital component in the immune process. It also participated in the growth, development, and metastasis of tumors. This study aimed to explore the prognosis of CXC chemokines in DLBCL and the relationship with immune infiltration through bioinformatics analysis. Methods: We systematically analyzed the expression level and prognostic value of CXC chemokines in DLBCL patients, and the correlation between CXC chemokines and tumor immune infiltration through databases, such as Oncomine, GEO, GEPIA, GeneMANIA, DAVID, HPA, GenomicScape, and TIMER2.0. Results: With the comprehensive analysis of different databases, we found that CXC chemokines (CXCL1/2/5/6/7/8/9/10/11/12/13/14) had significantly higher transcription levels in DLBCL patients vs. the control groups. The up-regulation mRNA levels of CXCL1/2/6/7/10/12 were associated with poor prognoses in DLBC patients. Further enrichment analysis of CXC chemokines and their receptors revealed that they were related to the infiltration and metastasis of immune cells. Besides, we found that the expression of CXCL9/10/11 were significantly correlated with tumor-infiltrating lymphocytes (TILs) (B cells, CD8+ T cells, CD4+ T cells, macrophages, Treg cells, and NK cells) and immune checkpoints in DLBCL. Conclusion: Our study may provide novel understandings for CXC chemokines as immunotherapeutic targets and prognostic biomarkers in diffuse large B-cell lymphoma through systematic analysis. VL - 10 IS - 1 ER -
Information
Email: